Litcius/Paper detail

MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer

Christophe Vanhaver, Pierre van der Bruggen, Annika M. Bruger

2021Journal of Clinical Medicine82 citationsDOIOpen Access PDF

Abstract

Myeloid-derived suppressor cells (MDSCs) expand during pathological conditions in both humans and mice and their presence is linked to poor clinical outcomes for cancer patients. Studying MDSC immunosuppression is restricted by MDSCs' rarity, short lifespan, heterogeneity, poor viability after freezing and the lack of MDSC-specific markers. In this review, we will compare identification and isolation strategies for human and murine MDSCs. We will also assess what direct and indirect immunosuppressive mechanisms have been attributed to MDSCs. While some immunosuppressive mechanisms are well-documented in mice, e.g., generation of ROS, direct evidence is still lacking in humans. In future, bulk or single-cell genomics could elucidate which phenotypic and functional phenotypes MDSCs adopt in particular microenvironments and help to identify potential targets for therapy.

Topics & Concepts

ImmunosuppressionMedicineMyeloid-derived Suppressor CellPhenotypeImmunologyCancerSuppressorPathologicalTumor microenvironmentGenomicsCancer researchImmune systemGeneticsBiologyGenePathologyGenomeInternal medicineImmune cells in cancerImmune Response and InflammationInflammation biomarkers and pathways